Involvement of IL-33 in the pathogenesis of rheumatoid arthritis: the effect of etanercept on the serum levels of IL-33

References

• McInnes IB, Schett G. Cytokines in the pathogenesis of rheu-matoid arthritis. Nat Rev Immunol. 2007;7:429–42.
   PubMed Web of Science ®Google Scholar
• Janossy G, Panayi G, Duke 0, Bofill M, Poulter LW, Goldstein G. Rheumatoid arthritis: a disease of T-Iymphocyte/macrophage immunoregulation. Lancet. 1981;17(2):839–42.
   Google Scholar
• Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440.
   PubMed Web of Science ®Google Scholar
• Ulfgren AK, Lindblad S, Klareskog L, Andersson J, Andersson U. Detection of cytokine producing cells in the synovial mem-brane from patients with rheumatoid arthritis. Ann Rheum Dis. 1995;54:654–61.
   Google Scholar
• Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheu-matoid arthritis. Arthritis Rheum. 1998;41:1258–65.
   PubMed Web of Science ®Google Scholar
• Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol. 2001;19: 163-96.
   Google Scholar
• Kageyama Y, Takahashi M, Torikai E, Suzuki M, Ichikawa T, Nagafusa T, Koide Y, Nagano A. Treatment with anti-TNF-alpha antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritis. Clin Rheumatol. 2007;26:505–9.
   PubMed Web of Science ®Google Scholar
• Kageyama Y, Ichikawa T, Nagafusa T, Torikai E, Shimazu M, Nagano A. Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3 alpha in patients with rheumatoid arthritis. Rheumatol Int. 2007;28:137–43.
   PubMed Web of Science ®Google Scholar
• Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McCl-anahan TK, et al. IL-33, an interleukin- 1-like cytokine that sig-nals via the IL-1 receptor-related protein 5T2 and induces T helper type 2-associated cytokines. Immunity. 2005;23: 479–90.
   Google Scholar
• Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 2009;60: 738–49.
   PubMed Web of Science ®Google Scholar
• Xu D, Jiang HR, Kewin P, Li Y, Mu R, Fraser AR, et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA. 2008;105:10913–8.
   PubMed Web of Science ®Google Scholar
• Xu D, Jiang HR, Li Y, Pushparaj PN, Kurowska-Stolarska M, Leung BP, et al. IL-33 exacerbates autoantibody-induced arthri-tis. J Immunol. 2010;184: 2620–6.
   Google Scholar
• Wood IS, Wang B, Trayhurn P. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adi-pocytes. Biochem Biophys Res Commun. 2009;384: 105–9.
   Google Scholar
• Ichikawa T, Kageyama Y, Kobayashi H, Kato N, Tsujimura K, Koide Y. Etanercept treatment reduces the serum levels of interleukin-15 and interferon-gamma inducible protein-10 in patients with rheumatoid arthritis. Rheumatol Int. 2010;30: 725–30.
   PubMed Web of Science ®Google Scholar
• Kageyama Y, Kobayashi H, Kato N. Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis. Mod Rheumatol. 2009;19: 657–62.
   Google Scholar
• Kageyama Y, Kobayashi H, Kato N, Shimazu M. Etanercept reduces the serum levels of macrophage chemotactic protein-1 in patients with rheumatoid arthritis. Mod Rheumatol. 2009;19: 372–8.
   PubMed Web of Science ®Google Scholar
• Musacchio E, Valvason C, Botsios C, Ostuni F, Furlan A, Ramonda R, et al. The tumor necrosis factor-alpha-blocking agent infliximab inhibits interleukin 1 beta (IL-lbeta) and IL-6 gene expression in human osteoblastic cells. J Rheumatol. 2009;36: 1575–9.
   PubMed Web of Science ®Google Scholar
• Mu R, Huang HQ, Li YH, Li C, Ye H, Li ZG. Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis. J Rheumatol. 2010;37:2006–13.
   PubMed Web of Science ®Google Scholar
• Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Ag-uilar L, et al. IL-33, the IL-1-like cytokine ligand for 5T2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA. 2007;104: 282–7.
   Google Scholar
• Leung BP, Xu D, Culshaw S, McInnes IB, Liew FY. A novel therapy of murine collagen-induced arthritis with soluble Tl/5T2. J Immunol. 2004;173: 145–50.
   Google Scholar
• Rank MA, Kobayashi T, Kozaki H, Bartemes KR, Squillace DL, Kita H. IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol. 2009;123:1047–54.
   PubMed Web of Science ®Google Scholar
• Kokkonen H, Soderstrom I, Rocklov J, Hallmans G, Lejon K, RantapaaDahlqvist S. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 2010;62:383–91.
   PubMed Web of Science ®Google Scholar
• Raza K, Falciani F, Curnow SJ, Ross RI, Lee CY, Akbar AN, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res 'Ther. 2005;7:784–95.
   PubMed Web of Science ®Google Scholar
• Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Thl- and Th2-type responses through its activity on human basophils, allergen-reactive 'Th2 cells, iNKT and NK cells. Int Immunol. 2008;20:1019–30.
   PubMed Web of Science ®Google Scholar
• Veni WA Jr, Souto FO, Vieira SM, Almeida SC, Fukada SY, Xu D, et al. IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann Rheum Dis. 2010;69:1697–703.
   PubMed Web of Science ®Google Scholar